Abstract:AIM:Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as potent drug development target for treating diabetes and obesity. Here, we designed and evaluated novel long-acting GLP-1R G protein biased agonist with potent clinical application. MAIN METHODS:GLP-1R G-protein biased sequences were screened via a high-throughput autocrine-based strategy and then fused to Exendin (9-39). These fusion peptides were further performed with site-specific modification. Surface plasmon resonance (SPR) measurements, GLP-1R activation potencies and plasma stability tests were applied to screen optimal candidate. Acute and chronic hypoglycemic and insulinotropic activities of selected agent were evaluated in diabetic and obese rodent animals. MAIN FINDINGS:AX09 exert highest binding affinities for GLP-1R extracellular domain (GLP-1R ECD). Further in vitro plasma stability and GLP-1R activation assays demonstrated better potency of AX18. Acute pharmacodynamic evaluation of AX18 demonstrated the promising insulinotropic and hypoglycemic activities which were exhibited in a dose-dependent manner. Prolonged hypoglycemic efficacies of AX18 were also observed in both hypoglycemic duration test and multiple oral glucose tolerance tests (OGTTs) in the diabetic mice. Further pharmacokinetic test in cynomolgus monkeys exhibited that the half-life of AX18 was more than 6 days. Once weekly treatment of AX18 in diabetic mice for 8-week achieved significantly improved %HbA1C, insulin resistance, glucose tolerance, β-cells and diabetic retinal injury. Chronic treatment of AX18 in diet-induced obese (DIO) mice also exhibited beneficial efficacies on %HbA1C, inflammation-related factors lowering, and weight gains. CONCLUSION:AX18, as a novel GLP-1R G protein biased agonist, exhibited potency for treating diabetes mellitus and its complications.

Recent Development of Exendin-4 and Its Analogs

Research Progress of Long-acting Exendin-4

Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.

In Vitro and in Vivo Characterization of a Novel Long-Acting GLP-1 Receptor Agonist, Exendin-4–Fc Fusion Protein

Bioactivity and Structure of Analogues of Exendin-4

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

A Site-Specific PEGylated Analog of Exendin-4 with Improved Pharmacokinetics and Pharmacodynamics in Vivo

The Research Actuality and Prospect on Exenatide,a Novel Therapy for Type 2 Diabetes

The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice

C-terminal Site-Specific PEGylated Exendin-4 Analog: A Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Diabetic Db/db Mice.

Novel DPP-4 Inhibitors Against Diabetes

Progress of extrapancreatic effects by glucagon-like peptide-1

Progress in the investigation of GLP-1 receptor agonists and DPP-Ⅳ inhibitors

Exenatide-loaded Glucose-Responsive Microspheres for Intelligent Diabetic Therapy

Exendin-4 Improves Glucose Metabolism in Insulin-Resistant Cells by Upregulating the Phosphorylative AMPK

Latest Progress in the Drug Development of Glucagon-Like Peptide 1 Analogues

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Novel Lipid Side Chain Modified Exenatide Analogs Emerged Prolonged Glucoregulatory Activity and Potential Body Weight Management Properties.

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Novel Glucagon- and OXM-based Peptides Acting Through Glucagon and GLP-1 Receptors with Body Weight Reduction and Anti-Diabetic Properties.